Table 4.

Correlation of TGF-β subtypes with OS and PFS in ovarian cancer patients treated with different chemotherapy strategies.

TGF-β subtypes	Chemotherapy	Cases	OS	P value	Cases	PFS	P value
			HR (95% CI)			HR (95% CI)
TGF-β1	Platin	1409	1.09 (0.95–1.26)	0.23	1259	1.08 (0.94–1.24)	0.27
	Taxol	793	0.86 (0.69–1.07)	0.18	715	0.85 (0.69–1.03)	0.094
	Platin+Taxol	776	0.88 (0.71–1.11)	0.28	698	0.86 (0.70–1.05)	0.13
TGF-β2	Platin	1409	1.20 (1.04–1.38)	0.0120∗	1259	1.46 (1.26–1.67)	0.001∗
	Taxol	793	1.27 (1.03–1.56)	0.025∗	715	1.43 (1.18–1.72)	0.0002∗
	Platin+Taxol	776	1.27 (1.03–1.57)	0.024∗	698	1.44 (1.20–1.74)	0.0001∗
TGF-β3	Platin	1409	1.20 (1.03–1.39)	0.016∗	1259	0.83 (0.72–0.96)	0.014∗
	Taxol	793	1.18 (0.97–1.43)	0.099	715	1.31 (1.10–1.55)	0.0024∗
	Platin+Taxol	776	1.19 (0.98–1.44)	0.085	698	1.31 (1.10–1.57)	0.0021∗
TGF-β4	Platin	1409	1.11 (0.95–1.29)	0.19	1259	0.85 (0.75–0.98)	0.02∗
	Taxol	793	1.13 (0.92–1.38)	0.24	715	1.15 (0.97–1.36)	0.12
	Platin+Taxol	776	1.16 (0.95–1.42)	0.16	698	1.17 (0.99–1.4)	0.07

^∗ P < 0.05.